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============

A great number of influenza cases are recorded in each epidemic season, although with varying intensity (Van-Tam and Sellwood [@CR8]; Kissling et al. [@CR5]; Brydak [@CR1]). Influenza occurs in every climate and latitude. In Central Europe, the incidence of influenza and influenza-like illnesses usually starts increasing from January to March (Globinska and Kowalski [@CR4]; Brydak [@CR1]). In Poland, the number of cases of influenza and influenza-like illnesses in a single season varies from a few thousands to several million (Globinska and Kowalski [@CR4]; Brydak [@CR1]; Romanowska and Brydak [@CR7]). The recorded cases are tallied from the reports of family doctors who are on the frontline of contact with patients. Depending on the number of cases they report, the epidemiological and virological interpretation is conducted on a national scale as well as a comparative evaluation on a global scale.

The project Influenza Vaccine Effectiveness-Monitoring (I-MOVE) is part of the European research coordinated by the ECDC, the primary purpose of which is to monitor the effectiveness of influenza vaccination in Europe during the growth of the disease (Kissling et al. [@CR5]). The project has been implemented in 12 countries in the European Union. Poland joined this program for the first time in the epidemic season of 2010/2011.

Methods {#Sec2}
=======

The preparation of this manuscript was approved by an Institutional Board for Research. The material consisted of 210 swabs from the nose and throat taken by primary care physicians who classified patients of all ages with symptoms of upper respiratory tract infection for the examination according to the European criteria for influenza-like illness (ECDC [@CR3]). Detection of the genetic material of influenza virus was performed by an RT-PCR method in the Voivodeship Sanitary-Epidemiological Stations. The collection and validation process of virological data was coordinated by the Influenza Virus Research Institute of the National Center for Influenza in Warsaw, Poland. The tests were designed to investigate the genetic presence of RNA of influenza viruses A and B, and also that of another 15 respiratory viruses, including Human parainfluenza virus type 1--4, Human respiratory syncytial virus type A and B, Human coronavirus 229E/NL63 and OC43, Human rhinovirus type A, B, and C, Human enterovirus, and Human adenovirus (RV 15 OneStep ACE Detection; Seegene, Seoul, South Korea). The methodology consisted of the determination in the reaction mixture of specific amplification product corresponding by its multiplicity to the fragment of a searched virus genome, limited at both sides with the sequences of primers used in the PCR. In order to estimate the size of the resulting PCR product, it was necessary to conduct a comparative analysis with the pattern of the size of DNA which contained fragments of various known sizes of DNA. The reading was performed by applying Amplicon to the agarose gel and carrying out an electrophoretic separation of the swabs, followed by inspecting and documenting the results with a GelDoc device and Quantity One software (Bio-Rad; Hercules, CA).

Collection of Clinical Material for Testing {#Sec3}
-------------------------------------------

Obtaining a reliable laboratory result of a virological test depends on a number of factors, most of which depend on the physician's collecting the material. They include the following:type of material and how it is collectedtime of sample collection after the onset of diseasestorage conditions of material until it is transported to the laboratoryconditions and time of transporting a sample to the laboratoryFailure to meet the specified requirements may result in a false negative result, which may have an impact on patients' treatment (Wozniak-Kosek and Brydak [@CR9]; Romanowska and Brydak [@CR7]). The optimal time for the sample collection is within 4--5 days, when symptoms are the strongest. The material could be a swab from the nose or throat, nasopharyngeal washes, aspirates from the nasopharynx, or the cerebrospinal fluid (Nitsch-Osuch et al. [@CR6]; Wozniak-Kosek and Brydak [@CR9]). Each sample taken from a patient and sent to the laboratory included information about the patient's age, gender, influenza vaccination, the anti-viral medicines taken, the onset of symptoms, and the date of material collection.

Results and Discussion {#Sec4}
======================

Of the 210 samples obtained from physicians participating in the I-MOVE project, detection of respiratory viral genetic material was successful in 152 cases (72.4 %). Other pathogens responsible for respiratory tract infections, in addition to bacteria and viruses, were fungi and parasites. Figure [1](#Fig1){ref-type="fig"} presents the percentage of viruses detected in clinical specimens.Fig. 1**Infections caused by influenza and influenza-like viruses** causing respiratory disease in Poland in 2010--2011 epidemic season; investigated within the I-MOVE project

The results show that influenza and other respiratory viruses are a major clinical, virological, and epidemiological problem. In the samples from the epidemic season of 2010--2011 in the I-MOVE project, the presence of the genetic material of influenza virus type A and B was detected in 81 cases, which represented 38.6 % of all samples investigated; the share held by the influenza virus type A/H1N1/pdm09 is shown in Fig. [2](#Fig2){ref-type="fig"}. In the remaining 71 positive samples, i.e., 33.8 %, the following respiratory viruses were detected: Human parainfluenza virus type 1--4, Human respiratory syncytia virus type A and B, Human coronavirus 229E/NL63 and OC43, Human rhinovirus type A, B, and C, Human enterovirus, and Human adenovirus.Fig. 2**Infections caused by influenza A** non-subtype and influenza A/H1N1/pdm09 in Poland in 2010--2011 epidemic season; investigated within the I-MOVE project

In 23 (11 %) cases, a co-infection with two respiratory viruses was reported, which constitutes a serious clinical problem because of the lack of suitable, effective antiviral drugs. The neuraminidase inhibitors, such as oseltamivir and zanamivir, are suitable only influenza treatment. These drugs are not effective in preventing infections caused by other viruses in the respiratory system. The arrangement of co-infecting viral pairs detected is presented in Table [1](#Tab1){ref-type="table"}.Table 1Respiratory virus co-infectionsType of co-infectionPositive samplesHuman parainfluenza virus 21Human respiratory syncytial virus B, Influenza BHuman coronavirus 229E/NL631Influenza AHuman rhinovirus4Human respiratory syncytial virus AHuman respiratory syncytial virus A1Influenza BHuman parainfluenza virus 31Human coronavirus OC43Human parainfluenza virus 31Human rhinovirusInfluenza A1Human parainfluenza virus 4Human adenovirus1Influenza AHuman parainfluenza virus 11Human respiratory syncytial virus BHuman adenovirus1Human parainfluenza virus 3Human rhinovirusHuman respiratory syncytial virus B2Human parainfluenza virus 4Influenza B2Human parainfluenza virus 4Human respiratory syncytial virus B2Influenza BHuman respiratory syncytial virus B1Human parainfluenza virus 1Influenza A2Human enterovirusHuman parainfluenza virus 21Influenza ATotal23

Outbreaks of the influenza and influenza-like viruses occur every epidemic season, covering 5--25 % of the world's population (Brydak [@CR1]). For many years, medicine has been using molecular biology methods of a rapid viral diagnosis that is beneficial not only for the individual patient but also results in the economic benefits for the country (Van-Tam and Sellwood [@CR8]). The most cost-effective way to combat influenza is prevention and vaccination. Viruses infecting epithelial cells of the respiratory tract cause a diverse defense response of the organism and try in different ways to avoid the immune mechanisms aimed at eliminating infectious agents (Globinska and Kowalski [@CR4]). An understanding of ways by which viruses avoid body's antiviral response may serve as a tool for developing new methods for treatment of respiratory diseases. The integrated epidemiological and virological influenza surveillance system conducted in Poland (Brydak et al [@CR2]; Wozniak-Kosek and Brydak [@CR9]), as well as international projects such as I-MOVE, significantly contribute to the evaluation of the spread of the influenza and other respiratory viruses in the population investigated. Such programs also allow assessing and comparing the epidemiological and virological situation in different countries, which results in a greater awareness of vaccinations, such as against influenza.
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